Trial Profile
An open-label, prospective study evaluating efficacy and safety of \intravitreal aflibercept for the treatment of Choroidal Neovascularization secondary to presumed ocular histoplasmosis syndrome.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Feb 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Choroidal neovascularisation
- Focus Adverse reactions; Therapeutic Use
- 13 Feb 2017 New trial record